After the expiration of global blockbuster drug patents, the rapid development of generic drugs has brought an explosive growth in the demand for API and intermediates, which can be dated back to omeprazole and other products from the 1990s, bringing huge profits to Indian pharmaceutical companies a......

Gastric cancer drug market broad competition pattern continues to reshape, the giants have poured in

The second domestic CDK4/6 inhibitor is about to be approved

After comparing ALPROSTADIL with various PDE5 inhibitors, the researchers found that men who took PDE5 inhibitors for Ed as well as stability coronary artery disease not only reduced their risk of a new heart attack, and it increases life expectancy.

The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol-Myers Squibb's (BMS) blockbuster PD-1 inhibitor Opdivo (nivolumab) in combination with chemotherapy as a first-line treatment for advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer and esophageal aden......

On May 25, Beijing time, Immunity, a leading international journal of immunology, published the latest results of the collaboration between the Gulou Hospital Affiliated to the School of Medicine of Nanjing University and the Institute of Modern Biology of Nanjing University. The research team led b......